Jenny McVey, PhD, is the North America compliance officer for bioMerieux, Inc. Prior to her current role, she led the Risk Strategy & Mitigation program for ethics and compliance for Novo Nordisk Inc. She has 15 years of experience in the life science industry, focusing on health care fraud and abuse matters related to pharmaceutical, medical device, and biotechnology manufacturers. Her experiences include developing future-state compliance strategies, corporate integrity agreement readiness, and compliance RAMP—health care compliance risk management—around medical affairs and commercial operations, third-party engagement, FCPA/ABAC matters, global commercialization product launches, global medical education, field sales training, and running device preclinical filing studies for filing with the FDA. Professor McVey has been recognized by multiple publications within the Policy & Medicine Compliance Update newsletter for developing innovative methodologies to measure compliance effectiveness. She has a PhD in biomedical sciences—cardiovascular physiology from the John A. Burns School of Medicine at the University of Hawaii at Manoa and has spent her career within the industry as well as within PwC and KPMG, applying her knowledge and expertise to build and enhance compliance programs.